ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $82.03, for a total transaction of $41,015.00. Following the sale, the vice president directly owned 77,890 shares of the company’s stock, valued at approximately $6,389,316.70. This trade represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $78.16, for a total transaction of $39,080.00.
• On Monday, April 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $77.95, for a total transaction of $38,975.00.

ANI Pharmaceuticals Stock Up 0.7%

Shares of NASDAQ ANIP opened at $82.29 on Tuesday. The stock has a market cap of $1.87 billion, a P/E ratio of 20.83 and a beta of 0.44. The firm has a 50 day moving average price of $79.88 and a 200 day moving average price of $79.41. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a 52-week low of $62.14 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts expect that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ANIP. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Maryland State Retirement & Pension System raised its position in ANI Pharmaceuticals by 5.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after acquiring an additional 134 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after acquiring an additional 143 shares in the last quarter. Illinois Municipal Retirement Fund raised its position in ANI Pharmaceuticals by 1.7% during the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after acquiring an additional 145 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in shares of ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 198 shares during the period. Finally, Oregon Public Employees Retirement Fund raised its position in shares of ANI Pharmaceuticals by 5.1% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock valued at $323,000 after purchasing an additional 200 shares during the period. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.